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Modulation of granulocyte LAM-i and MAC-i during dialysis—A
prospective, randomized controlled trial. Hemodialysis with first-use
cellulosic dialysis membranes results in activation of the alternative
pathway of complement and profound neutropenia followed by rebound
leukocytosis. The neutropenia has been shown to be associated with
increased expression of adhesion receptors and pulmonary sequestra-
tion of granulocytes. However, the mechanism underlying the return of
the granulocytes has not been elucidated. We determined simulta-
neously the changes in the granulocyte adhesion receptor MAC-i
(CD1 lb-CD 18) and the selectin LAM-I receptor during dialysis using a
complement activating and a non-complement activating membrane, in
a randomized, cross-over study. With initiation of dialysis with cellu-
losic membranes, there was a rapid and prominent increase in the
expression of MAC-i receptors. At the nadir of granulocyte count, 15
minutes after initiation of dialysis with the complement activating
membrane, there was a four-fold increase in the MAC-i receptor
expression. At the same time, there was a two-fold decrease in LAM-I
expression. There were no changes in the expression of two other
granulocyte receptors CDI Ia and CD15 which are known not to be
modulated during granulocyte activation. Granulocytes harvested dur-
ing dialysis and which had high MAC-i and low LAM-I expression had
a significantly decreased adherence to endothelial cell monolayers.
Dialysis of the same patients with non-complement activating mem-
branes resulted in no significant change in the expression of these
receptors on granulocytes nor in their adherence to endothelial cells.
These results shed new light on the mechanism of the cyclical granu-
locytopenia and rebound granulocytosis during dialysis with new cel-
lulosic membranes.
Hemodialysis with first-use cellulosic dialysis membranes
results in profound activation of the alternative pathway of
complement [1, 21. This is associated with a transient granulo-
cytopenia followed by a rebound granulocytosis [3]. In this
setting, granulocytes have been demonstrated to undergo acti-
vation, as demonstrated by degranulation and production of
reactive oxygen species [4—6]. In addition, up-regulation of
specific cell surface receptor proteins, including CR! [7] and
MAC-l (CD! lb-CD18) [81, the so-called integrin receptors,
have been demonstrated.
Several studies have clearly documented the importance of
the MAC-i receptor in adhesion of granulocytes to endothelium
and to other granulocytes. During dialysis with first-use cellu-
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losic membranes, Arnaout et al have previously demonstrated a
rapid up-regulation of granulocyte cell surface MAC-i (CD! ib-
CDI8) receptors [8]. The time course of increased cell surface
expression of this receptor coincided with the development of
granulocytopenia and their pulmonary sequestration, consistent
with the functional importance of increased cell surface MAC-!
expression in the increased adhesion of these activated granu-
locytes to the pulmonary endothelium. However, surprisingly,
granulocyte cell surface MAC- 1 remained elevated through
most of the course of dialysis, despite the egress of these
neutrophils from the pulmonary circulation and the reversal of
granulocytopenia beginning at 15 minutes after the initiation of
dialysis. Thus, while increased cell surface MAC-I expression
may be necessary in the development of dialysis granulocytope-
nia, it was not sufficient to maintain a granulocytopenic state.
The exact cause of the reversal of granulocytopenia has not
been demonstrated.
Recently a new family of cell adhesion molecules known as
selectins or LEC-CAMS have been described [9]. All members
of the selectin family appear to be involved in the adhesion of
circulating blood cells to endothelium. Kishimoto et al have
recently described shedding or down-regulation of the LAM-i
from human granulocytes in vitro upon activation with chemo-
tactic factors and phorbol esters, and proposed a potential role
for this shedding in regulating cell adhesion and transendothe-
hal migration [10]. To our knowledge, there are no studies to
date of human in vivo shedding of granulocyte LAM-!.
We postulated that granulocyte activation in vivo by first-use
cellulosic dialysis membranes may cause simultaneous up-
regulation of granulocyte cell surface MAC-i and down-regu-
lation of cell surface LAM- 1, and that the inverse regulation of
integrin and selectin granulocyte cell adhesion molecules during
hemodialysis may be involved in the sequence of initial devel-
opment and subsequent reversal of granulocytopenia in the
hemodialysis procedure. Furthermore, we postulated that these
reciprocal changes are initiated by complement activation and
therefore are attenuated either by the reuse of these cellulosic
membranes or during dialysis with synthetic membranes such
as PAN or PMMA, which do not activate complement.
Methods
Patient characteristics
Ten patients on chronic maintenance hemodialysis were
selected for study. Informed consent was obtained from the
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subjects and the project was reviewed by the Institutional
Review Board of the institution. The mean age of the patients
was 55 (range 27 to 75 years), with a mean time on dialysis of 1.5
years (range 6 months to 4 years). Seven were male and three
were female. None of these patients had clinical evidence of
infection at the time of the study. Prior to the study, all patients
were on a hemodialysis reuse program using 1% formaldehyde
incubated at 40°C for at least 24 hours as a sterilant. Bleach was
not used in the processing of these dialyzers.
Study design
All patients were studied in a cross-over fashion using
first-use cellulosic (Focus 90, National Medical Care, Rock-
leigh, New Jersey, USA) hemodialysis membranes—high com-
plement activating membranes—and fifth or greater reused
cellulosic dialysis membranes, which have minimal comple-
ment activating potential.
The sequence of sampling was random. Thus, in six studies,
patients were initially studied on first-use cellulosic membrane,
followed by fifth reuse sampling, whereas in four other
studies, the initial sampling was obtained during dialysis with a
reused ( fifth reuse) dialyzer, and patients were then placed on
a first-use dialyzer and sampled again. The interval between
these two studies for any one patient ranged from two weeks to
four months.
A bicarbonate based dialysate (Na 140 mEq/liter, K 2 mEq/
liter, Ca 3.5 mEq/liter, HCO3 30 mEq/liter, acetate 3 mEq/liter)
was used in all cases. Blood flow in all studies was 300 mllmin.
Blood samples were drawn pre-dialysis from the afferent line
and then subsequently from efferent lines at 5, 10, 15, 30, and 90
minutes after the initiation of dialysis and at the end of the
dialysis procedure. Anticoagulation was maintained using hep-
arm at an initial bolus of 100 U/kg, with additional doses if
activated clotting times were less than 1.5 times pre-dialysis
values.
Methods
Preparation of whole blood samples for measuring MAC-i
and LAM-i. Duplicate 100 .d aliquots of blood were removed
from the dialysis line at specified times. Ten microliters of
phycoerythrin conjugated anti-LEU- 15 (anti-PE-MAC- 1, Bec-
ton Dickinson, Mountainview, California, USA) was added to
one tube and 20 ul of fluorescein isothyocyanate conjugated
(FITC) anti-LEU-8 (FITC-anti-LAM- 1, Becton Dickinson) was
added to the other tube. These were incubated for 20 minutes at
4°C, washed x 1 with PBS (Difco Laboratories, Detroit, Mich-
igan, USA) and then resuspended in 850 d of PBS. Thirty
microliters of 1.67 mglml LDS-751 (Exciton, Dayton, Ohio,
USA) was added. This method allows the determination of
fluorescence in whole blood specimens and avoids the artifacts
that can potentially be introduced during granulocyte separa-
tion (see below) [11]. A 1:1 volume of 2% paraformaldehyde as
a fixative was then added to each tube. In subsequent experi-
ments, FITC conjugated antibody to CD! la (LFA-l; AMAC,
Westbrook, Maine, USA) and murine antibody to CD15 (Bec-
ton Dickinson) were added to whole blood and analyzed as
described above in three patients on first-use cellulosic dialyz-
ers. Goat anti-mouse (GAM-FITC) was used as the second
antibody for the CDI5 antibody (Coulter, Hileah, Florida,
USA). Control samples consisting of FITC-mouse IgG1 and
PE-mouse IgG2, (Becton Dickinson) were also processed
simultaneously. All samples were then analyzed within two
hours by flow cytometry.
Flow cytometric analysis of granulocyte MAC-i and LAM-I.
All samples were analyzed on a FACScan flow cytometer
(Becton Dickinson). The instrument was set to measure linear
forward light scatter (FSC) which is a measure of cell size,
linear side scatter (S SC), which is a measure of granularity, 530
nM fluorescein fluorescence (FL 1), 580 nM phycoerythrin fluo-
rescence (FL2), and >620 flM LDS-751 fluorescence (FL3).
Fluorescence parameters were collected using four decade
logarithmic amplification.
The instrument was triggered on FL3 so that only nucleated
cells staining with LDS-75! were detected. This effectively
eliminates erythrocytes from the analysis and permits analysis
of the major leukocyte populations in whole blood samples [11].
Data on at least 10,000 cells was collected in list mode files. For
in vitro experiments, 2000 events were collected.
Data analysis was performed by first displaying FSC versus
SSC and gating on the lymphocytes and granulocyte popula-
tions. Then histograms of FL1 or FL2 were generated for each
population, and the mean fluorescence level calculated. In some
studies two parameter correlated histograms of FL1 versus FL2
were also generated.
For each leukocyte population, control FL! and FL2 fluo-
rescence levels were determined from cells labeled with control
reagents consisting of FITC and PE conjugated mouse immu-
noglobulin (Becton Dickinson). The results are expressed as
mean log fluorescence channel (MLFC) of the test cells minus
the mean log fluorescence channel of the control. To facilitate
comparisons of fluorescence at different times, relative fluores-
cence is used to define the relative changes in receptor number.
Since a four decade, 1024 channel logarithmic scale was used,
the mean fluorescence channel could be converted to relative
fluorescence by the following formula:
Relative fluorescence =
10 (Test mean channel — Control mean channel /256
HUVEC cultures. Endothelial cells from human umbilical
cords were isolated by collagenase treatment and seeded on 100
mm petri dishes as described previously [12]. Morphology and
anti-factor VIII antibody staining confirmed the endothelial
origin of these cells. After confluence, cells were expanded by
successive passages on new petri dishes coated with 1% gelatin.
HUVEC were transferred to 24-well plates at passages 3 to 12
and used for adhesion experiments following confluence. PMN
from patients and normal donors were tested simultaneously on
HUVEC cultures from the same donor. In this series of
experiments, the PMN were obtained from patients on new
celluloscic membranes or PMMA (B2-150) membranes (Toray
Industries, New York, USA), which is known to cause only
minimal complement activation.
PMN isolation and Cr5' labelling. Ten milliliters of blood
were drawn in a chilled vacutainer tube containing 50 U heparin
from the efferent line of the dialyzer at time 0, 5, 15, 30, 60, 120
and 240 minutes (end of the session). All isolation procedures
were maintained at 4°C until the adhesion assay or unless
otherwise stated. PMN were separated by dextran sedimenta-
tion (vollvol) for 30 minutes and red cells were lysed by
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hypotonic shock with distilled water. This procedure obtained a
high recovery of PMN with a contamination of less than 10
5% monocytes as assessed by size and granularity on cytoflu-
orometry analysis. Approximately io PMN were incubated in
500 1d Hanks' balanced salt solution (HBSS) without Ca + and
Mg (Gibco Lab., Grand Island, New York, USA), with 100
pCi Cr' (1 mCiImI) (Du Pont NEN, Boston, Massachusetts,
USA) for one hour with frequent gentle shaking in order to
obtain a total labelling of 20,000 cpm/106 PMN. PMN were
washed twice and resuspended at 106/ml in HBSS containing
Ca and Mg and immediately assayed for adhesion to
endothelial cells as shown below.
Adhesion assay. A total of 5. iO PMN resuspended in 500 pi
HBSS + 1% HEPES (pH 7.4) were allowed to adhere in
duplicates on HUVEC wells at 37°C in a 5% CO2 incubator for
various amounts of time (5, 10, 15, 20, 30, 45 mm). At the end
of each time point, supernatants were harvested and wells
washed with cold HBSS. HUVEC monolayers and adherent
PMN were lysed with 500 pi 1 N NH4OH for one hour. The
amount of Cr5' in the supernatants, washes and lysis suspen-
sion was determined in a scintillation counter. Interassay vari-
ation was 4.2 1.8%. Percentage of adherent PMN was
determined as follows:
% adherence = mean of duplicates of
cpm (lysis + supernatant)
In vitro sti,nulation of granulocytes with C5a and PMA. In
this series of experiments C5a (1 x 10—8 M) (Sigma) or PMA
(100 nM) (Sigma) was added separately to 10 ml of whole blood
obtained from normals (N = 3) and dialysis patients (N = 3)and
maintained at 37°C. Aliquots were removed at selected time
points and analyzed for granulocyte cell surface MAC-i,
LAM-i, CD15 and CD! laICDl8 density as described above.
White blood cell measurement. White blood cell (WBC)
counts were measured using a Coulter Counter.
Statistical methods
Statistical analysis was performed using multivariate analysis
packages available in SAS (Statistical Analysis Institute, Cary,
North Carolina, USA). Initial analysis comparing changes in
receptor fluorescence intradialytically and between new and
reused dialyzers was done using the ANOVA procedure and the
DUNCAN multiple range test, with significance determined at
the P = 0.05 level. Specific values of the statistical differences
(P values) between pre-dialysis values and a specific time point
as well as for each time point between new and reused receptor
data was determined using post-hoc t-tests of adjusted treat-
ment means (least-square means).
Results
In vivo granulocyte LAM-i and MAC-i expression during
first-use cellulosic (complement activating) and non-
complement activating dialysis membranes
With first-use cellulosic dialysis membranes, granulocyte
LAM-I surface expression began to drop within five minutes
after the initiation of dialysis from a mean log channel fluores-
Time, minutes
Fig. 1. Granulocyte LAM-i modulation during dialysis with cellulosic
membranes. Whole blood was obtained at specified time points with
either first-use EU] or greater than fifth reuse cellulosic membranes [EJ],
Results are expressed as log mean fluorescence of granulocyte cell
surface LAM-I 5EM (N = 10 experiments). * = P < 0.05, ** = P <
0.001 compared to pre-dialysis values.
cence of 190 11 to 141 17 MLFC (P < 0.01; Fig. i).
Subsequently, LAM-i levels decreased further and reached a
nadir 15 minutes after the initiation of dialysis, at which point
mean channel fluorescence was 107 12 channels (P < 0.004
compared to pre-dialysis levels). This represents a 2.1-fold
decrease, to 47% of pre-dialysis levels. At the 30-minute
sampling time, there was a trend toward increasing granulocyte
LAM-i levels to 130 15 MLFC, though still significantly less
compared to pre-dialysis values (P < 0.002). By the end of
dialysis, granulocyte LAM-i levels had increased to 146 14
MLFC, not significantly different than pre-dialysis values.
Intradialytic changes of LAM-i receptors during dialysis with
non-complement activating membranes were markedly attenu-
ated. Thus, after 15 minutes, granulocyte LAM-i expression
had declined from 171 13 pre-dialysis to 164 18 MLFC (P
= NS; Fig. 1). By the end of dialysis, granulocyte LAM-l had
declined to 136 12 MLFC, which is not statistically different
from pre-dialysis values.
Changes in granulocyte cell surface MAC-! (CDilb-CD18)
were also analyzed intradialytically (Fig. 2). As has previously
been demonstrated, there was a dramatic up-regulation of
granulocyte cell surface MAC-i beginning within five minutes
after the initiation of new cellulosic hemodialysis, at a time
when there was no significant decrease in WBC values (vide
infra). By 15 minutes, fluorescence for cell surface MAC-i
increased to 308 25 MLFC compared to 161 22 channels
pre-dialysis (P < 0.003). This represents a four-fold increase
compared to pre-dialysis values. Cell surface granulocyte
MAC-l remained elevated compared to pre-dialysis, even at the
end of the dialysis session with new cellulosic dialysis mem-
branes. Thus at the end of dialysis, MLFC of MAC-i was 246
24 channels versus 161 22 channels pre-dialysis, representing
a 2.3-fold increase compared to pre-dialysis. Similar to the
LAM-! receptor, there were no statistical changes in MAC-i
expression during dialysis with reused membranes (Fig. 2).
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Time, minutes
Fig. 2. Granulocyte MAC-i (CD11b-CDJ8) modulation during hemo-
dialysis with cellulosic membranes. Whole blood was obtained at
selected time points with either first-use [U] or greater than 5th reuse
cellulosic membranes [0]. Results are analyzed as log mean fluores-
cence of granulocyte MAC-I SEM (N = 10 experiments). *P < 0.05,
= 0.001 compared to pre-dialysis values.
Taken together, these studies clearly demonstrate that com-
plement activation of granulocytes is associated with a rapid
and dramatic shedding of granulocyte cell surface LAM-I and
up-regulation of MAC-i receptors that does not occur with
non-complement activating membranes.
Two-parameter correlated plots of granulocyte LAM-I and
MAC-I expression during first-use cellulosic hemodialysis
Two-color immunofluorescence correlated plots of granulo-
cyte LAM-i and MAC-I cell surface expression during first-use
cellulosic hemodialysis were obtained. Figure 3 is a repre-
sentative bicontour plot obtained over the course of a single
hemodialysis session. Analysis of granulocytes obtained pre-
dialysis showed a relatively uniform population in expression of
both MAC-i and LAM-i. Five minutes after the initiation of
dialysis, MAC-i cell surface expression had increased in a
uniform fashion in all granulocytes; however, the decrease at
five minutes in LAM-i expression was more heterogeneous,
indicating that not all cells had shed their LAM-i receptors. The
heterogeneity of LAM-i expression continued through the first
15 minutes of dialysis. Thereafter, as LAM-i cell surface
expression decreased the population again became more uni-
form for all cells. By the end of the hemodialysis session, there
again was a single population of granulocytes in terms of both
MAC-I and LAM-i expression.
Spec j/icity of intradialytic granulocyte receptor changes
To establish the specificity of intradialytic granulocyte
LAM-i and MAC-i modulation during first-use cellulosic he-
modialysis, we used a combination of forward-angle light scat-
ter (FSC) and 90° side scatter (SSC) to flow cytometrically
isolate the lymphocyte population for analysis in five patients.
There were minimal changes in lymphocyte cell surface LAM-i
expression (Fig. 4) over the course of hemodialysis with either
first-use or multiply reused cellulosic membranes.
To determine the role of complement activation, we assessed
in in vitro experiments the changes of granulocyte receptors in
response to C5a. As can be seen for the LAM-i receptor in
* * Figure 5 for blood obtained from normal volunteers, incubation
of whole blood with C5a led to a decline of MLFC from 184
9 to 131 17 MLFC after five minutes of incubation. Thirty
minutes after incubation with C5a, there was a further decline in
LAM-i granulocyte expression to 92 20 MLFC. This repre-
sents a 2.1-fold decline, to 48% of control values.
Addition of PMA led to similar but more pronounced results
(Fig. 5). Thus, by five minutes after addition of PMA, mean log
channel fluorescence (MLFC) had declined from 184 9 to 39
22. This represents a 3.7-fold decline in the expression of
these receptors, to 27% of control values. There was no further
decline in these PMA stimulated cells after five minutes, and by
30 minutes, LAM-i expression had increased to only 75 18.
The addition of buffer as a control showed no effect on cell
surface LAM-i expression (Fig. 5).
The addition of either C5a or PMA to granulocytes in whole
blood obtained from normals also caused a rapid up-regulation
of granulocyte surface MAC-i expression (Fig. 6). Using PMA,
MLFC increased from 164 19 channels to 497 39 units over
30 minutes. This represents a 20-foid increase compared to
control values. With C5a, up-regulation of cell surface MAC-i
was equally prompt, but to a lower cell density than with PMA
(Fig. 6). Control values using buffer remained unchanged until
the 15 minute time point of incubation, after which there was a
slight increase in granulocyte MAC-i expression, from 164 19
to 260 49 MLFC. This most likely represents granulocyte
stimuiation during in vitro incubation at this temperature [13].
Identical results were obtained when the experiments were
repeated on blood obtained pre-dialysis from dialysis-depen-
dent patients (data not shown). Thus the addition of either C5a
or PMA on whole blood resulted in increased granulocyte
MAC-i cell surface expression and decreased granulocyte
LAM-i expression.
In other in vivo experiments, we investigated the intradialytic
changes of granulocyte receptors CD1 la and CD15 in response
to dialysis with new cellulosic membranes (Focus 90, National
Medical Care, Rockleigh, New Jersey). As can be seen in Table
1, these receptors had little or no change in their expression
intradialytically. The changes in the expression of either of
these receptors were not statistically significant.
White blood cell counts during first-use cellulosic dialysis
membranes
White blood cell (WBC) counts began to decline by 10
minutes after the initiation of dialysis (Table i). Note, however,
that at five minutes after initiation of dialysis, the number of
WBC was not significantly different from the pre-dialysis value.
By fifteen minutes after the initiation of new cellulosic hemo-
dialysis, blood cell counts had declined to 37% of pre-dialysis (P
< 0.001). White blood cell counts began to increase after 15
minutes, and by 90 minutes after the initiation of dialysis white
blood cell counts were not significantly different than pre-
dialysis. When cellulosic dialysis membranes were reused, the
changes in WBC were markedly attenuated (Table 2).
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Fig. 4. Lymphocyte LAM-I expression during dialysis with cellulosic
membranes. Whole blood was obtained at selected time points with
either first-use [] orgreater than fifth reuse cellulosic membranes [L].
A lymphocyte population was gated using flow cytometric criteria of
forward angle light scatter and 90° side scatter. Lymphocyte LAM-I
cell surface expression was expressed as log mean fluorescence SEM
(N = 5 experiments). < 0.05.
Fig. 3. Two color immunofluorescence of
granulocyte LAM-i and MAC-I expression
during a representative first-use cellulosic
hemodialysis. Whole blood was obtained at
selected time points over the course of first-
use cellulosic hemodialysis. Simultaneous two
color immunofluorescence was used to
analyze log mean fluorescence of granulocyte
LAM-i and MAC-i, respectively. Analysis
reveals a relatively uniform population pre-
dialysis. MAC-l cell surface expression is
uniform at all time points. The corresponding
decrease in LAM-i expression is more
heterogeneous over the first 30 minutes of
dialysis.
Time, minutes
Fig. 5. In vitro modulation of granulocyte LAM-I in response to
exogenous C5a and PMA. Whole blood was incubated with either C5a
(1 x 10—8 M) [•I, PMA (100 nM) [U], or buffer [Dl, at 37°C. Results are
expressed as log mean fluorescence SEM (N = 3 experiments).
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Adherence of intradialytic granulocytes to HUVEC
Percent of adherent granulocytes obtained from normal con-
trols, assessed in parallel with hemodialyzed subjects, in-
creased with time of exposure to HUVEC, reaching a plateau of
14.1 3.2% at 30 minutes of adhesion time to HUVEC and
remained at the same level at 45 minutes. Consequently, to
facilitate the comparison of adherence, we compared all adher-
ence values 45 minutes after incubating these granulocytes with
HUVEC. Day-to-day and inter-subject variability was less than
4%. Percent adherence of granulocytes harvested pre-dialysis
was in the same range (12.3 3.7% at 45 minutes) as controls
(P = NS), confirming that baseline adherence of these cells
from hemodialysis subjects was not significantly affected by the
uremic state. Adhesion of granulocytes harvested as soon as
five minutes after the initiation of first-use cellulosic membranes
was found to be markedly decreased at all HUVEC incubation
time points, compared to pre-dialysis levels (Fig. 7). Granulo-
cytes harvested at 15 minutes after initiation of dialysis with
new cellulosic membranes had percent adhesion to HUVEC as
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Table 1. Intradialytic changes in CDI Ia and CDI5 granulocyte receptors (N = 3)
Time Pre
5 10 15 30 90
minutes
CDIIa(LFA-1) 183 9.7 180 11.2 200 22.9 186 31 179 12.9 165 4.9
CD15 545 29.1 521 26.3 464 27.4 514 41.3 559 6.4 543 7.7
50
Time, minutes
Fig. 6. In vitro modulation of granulocyte MAC-I after incubation with
exogenous C5a and PMA. Whole blood was incubated with either C5a
(1 X 108M) [s], PMA (100 nM) jai, or buffer [U], at 37°C. Granulocyte
MAC-I fluorescence was analyzed as log mean fluorescence SCM (N
= 3 experiments).
low as 2.42 2.1% (P < 0.001 compared to pre-dialysis
samples). This was comparable to adherence on uncoated
plastic dishes (data not shown). Adhesion of granulocytes
harvested at 60 minutes of dialysis with this complement
activating membrane remained persistently low (<6%) and
recovered slightly toward the end of the dialysis session (7.9
2.8%). When granulocytes from the same patients were har-
vested during dialysis with non-complement activating mem-
branes, no intradialytic changes in adherence occurred (Fig. 7).
Discussion
The mechanisms that cause granulocytopenia, and in partic-
ular its subsequent reversal during dialysis with new cellulosic
membranes, have not been entirely elucidated. Previously,
investigators have postulated that the development of granulo-
cytopenia is related to C5a-induced granulocyte leukoaggrega-
tion and adhesion to endothelial cells. On the other hand, the
reversal of granulocytopenia was attributed to down-regulation
of the number and/or functional activity of granulocyte C5a
receptors [14—16]. However, this hypothesis has recently been
disputed by the demonstration that there is little if any down-
regulation of granulocyte C5a receptors during first-use cellu-
losic dialysis [17, 18].
In this study, we have confirmed the time course of increased
granulocyte cell surface MAC-I expression and its association
with the development of granulocytopenia, suggesting that
Table 2. White blood cell counts (x l0) during new and reuse (>5)
cuprophane dialysis
Time New Reuse
Pre 7.3 0.6 7.6 0.4
5mm 7.1±0.9 7.6±0.4
10 mm 3.9 1.2° 7.3 0.5
15 mm 2.7 07b 7.2 0.6
30 mm 4.9 06b 7.5 0.4
90 mm 7.6 0.8 7.7 0.3
240 mm 6.9 0.8 6.7 0.4°
increased cell surface MAC-i expression may indeed be in-
volved in increased granulocyte adhesiveness to endothelium,
resulting in granulocytopenia. Of interest is that the increased
expression of MAC-i appears to precede the development of
granulocytopenia. These results confirm those of Arnaout et al
[8]. However, in the present study as well as in Arnaout et al's
study, granulocyte cell surface MAC-i receptors remain ele-
vated throughout most of the course of hemodialysis, despite
the reversal of granulocytopenia starting as early as 15 minutes
after initiation of dialysis and the return of WBC count to
pre-dialysis levels 60 minutes after the initiation of dialysis.
Thus, while increased cell surface MAC-I expression may be
necessary in the development of dialysis granulocytopenia, it is
not sufficient to maintain a granulocytopenic state.
Recently, a new family of cell adhesion molecules, known as
selectins or LEC-CAMs, have been described. All three mem-
bers of this family appear to have carbohydrate moieties as their
ligands, and appear to be involved in the adhesion of circulating
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Fig. 7. Percent adherence of granulocytes to endothelial cell monolay-
ers. Granulocytes were harvested from blood drawn at different times
after initiation of dialysis with complement activating membrane (•)
and a non-complement activating membrane (U).
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blood cells to endothelium. The LEC-CAM GMP-140 (CD 62),
found on activated platelet and endothelial cell plasma mem-
branes has been demonstrated to bind granulocytes and mono-
cytes [19—22]. A second member of this family, known as
ELAM-i, is found solely on activated endothelial cells and is
involved in leukocyte adhesion [23]. The most recent member
of this family to have its structure elucidated is LAM-i (also
previously known as LEU-8, TQ-i, LEC-CAM-l and its murine
equivalent as MEL-l4) [24]. LAM-I is found on granulocytes,
monocytes, lymphocytes and their precursor cells, and has an
unknown ligand found on endothelial cells [25, 26]. Kishimoto
et al have recently described shedding of LAM-i from human
granulocytes in vitro upon activation with chemotactic factors
or phorbol esters [10]. Shedding of LAM-i from activated
granulocytes has been postulated to prevent extravasation into
and damage of normal tissues by activated granulocytes [27]. In
an animal model, Jutila et al demonstrated that "high MAC-i,
low LAM-I" granulocytes are not able to transmigrate endo-
thelium at a site of inflammation into a focus of infection [27].
In this study, we have demonstrated that coincident with the
reversal of granulocytopenia, granulocyte LAM-i surface
expression reaches a nadir at 15 minutes and only returns
towards pre-diaiysis values toward the end of dialysis. The
shedding of the LAM- 1 receptor is likely a result of complement
activation since it occurred with complement activating sur-
faces in vivo and were reproduced in vitro in response to C5a.
These changes are specific for the granulocytes, as shown by
the absence of similar changes in lymphocytes.
We were also able to demonstrate that granulocytes har-
vested between 5 and 60 minutes after initiation of first-use
cellulosic membrane hemodialysis have dramatically decreased
binding to endothelial monolayers. Granulocytes harvested
intradialytically using PMMA, a non-complement activating
dialysis membrane, did not change significantly compared to
pre-dialysis values. The temporal relationship between the
development of "high MAC-i, low LAM-i" granulocytes in
circulation and decreased binding of granulocytes to endothelial
cells, strongly support the contention that changes in granulo-
cyte cell surface adhesion expression govern the initial devel-
opment of granulocytopenia and its subsequent reversal and
cause the complement mediated changes in white blood cells
during cellulosic dialysis.
We postulate that during the early (first 5 mm) stages of
first-use cellulosic hemodialysis, complement activation leads
to rapid and prominent up-regulation of MAC-i on granulocyte
cell surfaces. The increased density of MAC-i on these granu-
locytes leads to increased adhesiveness both to other granulo-
cytes and to endothelium resulting in granulocytopenia. In the
absence of transendothelial migration (and possibly endothelial
cell activation), activated granulocytes shed their LAM-i re-
ceptors and detach from the endothelium since these "high
MAC-I, low LAM-i" granulocytes have decreased endothelial
cell adherence. This leads to the reversal of granulocytopenia.
It is only by the end of dialysis that the expression of LAM-l on
granulocytes has returned to near basal levels and the binding of
granulocytes to endothelial cell monolayers is partially re-
stored. Note, however, that at the end of dialysis with the
complement activating membrane, the level of MAC-i is still
substantially above baseline level.
It is possible to speculate that these observations may have
clinical implications. Infections remain one of the leading
causes of morbidity and mortality in patients on chronic main-
tenance hemodialysis. Many of these infections are vascular
access-related and occur during or around the time of the
dialysis procedure [28, 29]. Thus, the "high MAC-I, low
LAM-i" granulocyte state that occurs during first-use cellulo-
sic hemodialysis could prevent granulocyte transmigration into
sites of infection. Furthermore, granulocytes stimulated by
cellulosic membranes will not respond to additional stimuli such
as FMLP or C5a in elaborating reactive oxygen species during
the dialysis procedure [5, 6]. Vanholder et al have demon-
strated, in a prospective study, higher rates of infections and
hospitalization in patients chronically dialyzed with comple-
ment activating membranes compared to polysulfone dialyzed
patients [301. However, whether changes in granulocyte func-
tion during first-use cellulosic hemodialysis contributes to mor-
bidity from infections in hemodialysis patients will require
further study in the future.
In summary, we have demonstrated that during first-use
cellulosic hemodialysis, there is a rapid and pronounced up-
regulation of the granulocyte integrin cell adhesion molecule
MAC-i, but in addition, down-regulation of granulocyte LEC-
CAM molecule LAM-i occurs. Furthermore, the reciprocal
changes in granulocyte cell adhesion molecules coincide with
decreased adhesion to endothelial cell monolayers. Changes in
granulocyte cell adhesion molecules may explain development
of neutropenia and subsequent reversal in first-use cellulosic
membrane hemodialysis.
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